Young‐Kwang Yoon

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock‐Ah Im, Young‐Kwang Yoon et al. · Molecular Cancer Therapeutics · 2013 · 141 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han et al. · Molecular Carcinogenesis · 2010 · 127 citations

Medicine, Molecular Biology, Oncology +17

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2

Hwang‐Phill Kim, Young‐Kwang Yoon, Jin‐Won Kim et al. · PLoS ONE · 2009 · 117 citations · Full text

Medicine, Oncology, Pharmacology +15

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

Jin Won Kim, Hwang‐Phill Kim, Seock‐Ah Im et al. · Cancer Letters · 2008 · 117 citations

Medicine, Oncology, Pharmacology +17

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han et al. · Molecular Cancer Therapeutics · 2009 · 71 citations

Medicine, Oncology, Pharmacology +16